These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 38716830)

  • 21. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
    Barresi V; Musmeci C; Rinaldi A; Condorelli DF
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.
    Aupy P; Echevarría L; Relizani K; Goyenvalle A
    Biomedicines; 2017 Dec; 6(1):. PubMed ID: 29271929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery.
    Gagliardi M; Ashizawa AT
    Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33923688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications.
    Sergeeva OV; Shcherbinina EY; Shomron N; Zatsepin TS
    Nucleic Acid Ther; 2022 Jun; 32(3):123-138. PubMed ID: 35166605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
    Sahin I; George A; Seyhan AA
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent progress and prospect in oligonucleotide therapeutics].
    Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T
    Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of splice-switching oligonucleotides.
    Bauman J; Jearawiriyapaisarn N; Kole R
    Oligonucleotides; 2009 Mar; 19(1):1-13. PubMed ID: 19125639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
    Li D; Mastaglia FL; Fletcher S; Wilton SD
    Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
    Mercatante DR; Sazani P; Kole R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Discovery Perspectives of Antisense Oligonucleotides.
    Kim Y
    Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
    Quemener AM; Centomo ML; Sax SL; Panella R
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies.
    Li D; McIntosh CS; Mastaglia FL; Wilton SD; Aung-Htut MT
    Transl Neurodegener; 2021 May; 10(1):16. PubMed ID: 34016162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders.
    Hill SF; Meisler MH
    Dev Neurosci; 2021; 43(3-4):247-252. PubMed ID: 34412058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Antisense Oligonucleotides Are Coming of Age.
    Bennett CF
    Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Splice-switching antisense oligonucleotides as therapeutic drugs.
    Havens MA; Hastings ML
    Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. More than a messenger: Alternative splicing as a therapeutic target.
    Black AJ; Gamarra JR; Giudice J
    Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194395. PubMed ID: 31271898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
    De Serres-Bérard T; Ait Benichou S; Jauvin D; Boutjdir M; Puymirat J; Chahine M
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
    Haque US; Yokota T
    Cells; 2023 Oct; 12(19):. PubMed ID: 37830609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic antisense oligonucleotides for movement disorders.
    Doxakis E
    Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases.
    Xue K; MacLaren RE
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1163-1170. PubMed ID: 32741234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.